Timothy P Tully

US Patent:

7968524, Jun 28, 2011

Filed:

May 15, 2008

Appl. No.:

12/121731

Inventors:

Marco Peters - La Jolla CA, US
Roderick Euan Milne Scott - Poway CA, US
Timothy P. Tully - Solana Beach CA, US

Assignee:

Helicon Therapeutics, Inc. - San Diego CA

International Classification:

A61K 31/70
C07H 21/04

US Classification:

514 44, 536 245

Abstract:

The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function.

US Patent:

20090053140, Feb 26, 2009

Filed:

May 15, 2008

Appl. No.:

12/121742

Inventors:

Roderick Euan Milne Scott - Poway CA, US
Rusiko Bourtchouladze - New York NY, US
Marco Peters - La Jolla CA, US
Timothy P. Tully - Solana Beach CA, US

International Classification:

A61K 49/00

US Classification:

424 91

Abstract:

The present invention relates to a method of identifying a gene or gene product associated with transcription dependent memory formation in an animal comprising the steps of: (a) administering to said animal sufficient small interfering RNA (siRNA) specific for the gene to inhibit gene function; (b) training said animal under conditions sufficient to induce transcription dependent memory formation in a normal untreated animal; and (c) determining the level of transcription dependent memory formation induced by the training of the treated animal. The present invention provides methods of using small interfering PNAs (siRNA) in hippocampus to identify genes and gene product whose inhibition affects contextual and temporal long-term (LTM) memory, but not short-term memory (STM).

US Patent:

20100028839, Feb 4, 2010

Filed:

Jul 17, 2009

Appl. No.:

12/505454

Inventors:

Timothy P. Tully - Solana Beach CA, US
Lila Davachi - New York NY, US

International Classification:

G09B 19/00

US Classification:

434236

Abstract:

The present invention provides methods and systems for identifying, evaluating, and testing various compounds as memory agents and regimens as training protocols related to memory enhancement and/or impairment. Such methods and systems may test any compounds or protocols, including the memory agents and training protocols described herein. The methods can comprise combining training protocols with the general administration of memory agents. In some embodiments, the present invention may involve identifying, selecting, testing, evaluating or assessing a compound as a drug candidate for a memory agent, for example, as one effective for enhancing or impairing memory.

US Patent:

20100285990, Nov 11, 2010

Filed:

Dec 29, 2008

Appl. No.:

12/810617

Inventors:

Timothy P. Tully - Solana Beach CA, US
Marco Peters - La Jolla CA, US
Roderick E. Scott - Poway CA, US

International Classification:

C40B 30/06
C40B 30/00

US Classification:

506 10, 506 7

Abstract:

The disclosed invention relates to cell based screening assays that are useful to identify compounds that enhance memory in normal and memory impaired individuals.

US Patent:

20110076235, Mar 31, 2011

Filed:

Sep 29, 2010

Appl. No.:

12/893236

Inventors:

Timothy P. Tully - Solana Beach CA, US
Hollis T. Cline - Solana Beach CA, US

International Classification:

A61K 49/00
C12Q 1/68
C12Q 1/02
C12Q 1/06
C07H 21/00
C07H 21/02
A61K 31/7088
A61K 31/713
A61P 25/00

US Classification:

424 92, 435 6, 435 29, 435 39, 536 245, 514 44 A

Abstract:

The present disclosure provides methods for investigating neurogenesis, neural cell proliferation and differentiation. Specifically, the present disclosure relates to methods for identifying pharmaceutical agents capable of modulating neurogenesis and neural cell proliferation, methods of screening for genes that modulate neurogenesis and proliferation of neural progenitor cells, and methods of identifying pharmaceutical agents as candidate modulators of neurogenesis and neural proliferation or differentiation. The present disclosure also relates to methods for identifying pharmaceutical agents to characterize and modulate neurogenesis, pharmaceutical agents identified by such methods, methods for treating patients with such pharmaceutical agents, and compositions containing such pharmaceutical agents. Accordingly, the present methods enable elucidation of the mechanisms that control neurogenesis, brain development and function in healthy animals and in disorders of the nervous system. Furthermore, the present methods facilitate the development of compositions to prevent, improve or stabilize impaired neurogenesis in various nervous system disorders, including cognitive disorders.

US Patent:

20110093206, Apr 21, 2011

Filed:

Apr 30, 2010

Appl. No.:

12/772030

Inventors:

Philip Cheung - San Diego CA, US
Timothy P. Tully - Solana Beach CA, US
Oscar Moreno - Rio Piedras PR, US

International Classification:

G06F 17/18
G06F 19/00

US Classification:

702 19, 702181

Abstract:

Methods, systems and products are provided to quantitatively measure the degree of concordance between or among microarray probe level data sets. These can include the steps of evaluating outlier probe values, determine gene expression scores, evaluating the significant treatment effect for each gene expression score, and determining concordance between replicate data sets

US Patent:

20110281936, Nov 17, 2011

Filed:

Jun 27, 2011

Appl. No.:

13/169739

Inventors:

Marco Peters - La Jolla CA, US
Roderick Euan Milne Scott - Poway CA, US
Timothy P. Tully - Solana Beach CA, US

International Classification:

A61K 31/713
A61P 25/00
C12Q 1/68

US Classification:

514 44 A, 435 612

Abstract:

The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent protein expression. The present invention further provides methods for treating a defect in long term memory formation by inhibiting Gpr12 function and methods for treating a defect in performance of a hippocampal-dependent cognitive task by inhibiting Gpr12 function.

US Patent:

20120171124, Jul 5, 2012

Filed:

Feb 2, 2012

Appl. No.:

13/364504

Inventors:

Timothy P. Tully - Solana Beach CA, US
Roderick E.M. Scott - New York NY, US
Rusiko Bourtchouladze - New York NY, US

International Classification:

A61K 49/00
G01N 21/64

US Classification:

424 92, 435 613

Abstract:

The present invention provides methods for identifying cognitive enhancers able to enhance CREB pathway function. Cognitive enhancers identified in accordance with the invention can be used in rehabilitating an animal with cognitive dysfunctions and for enhancing memory or normal cognitive performance (ability or function) in a normal animal.